CoChat
Sign Up
Cited by 641Gout, Hyperuricemia, Uric AcidDrug-Induced Adverse ReactionsBiochemical and Molecular Research

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

Schumacher, H. RALPH, Becker, Michael A., Wortmann, Robert L., MacDonald, Patricia A., Hunt, Barbara, Streit, Janet, Lademacher, Christopher, Joseph‐Ridge, Nancy·2008·Arthritis Care & Research
DOI 10.1002/art.24209
Open this paper in CoChat — free account

Abstract

Objective: To compare the urate‐lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function. Methods: Subjects (n = 1,072) with hyperuricemia (serum urate level ≥8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to ≤2.0 mg/dl) renal function were randomized to receive once‐daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks. Results: Significantly ( P ≤ 0.05) higher percentages of subjects treated with febuxostat 80 mg (48%), 120 mg (65%), and 240 mg (69%) attained the primary end point of last 3 monthly serum urate levels <6.0 mg/dl compared with allopurinol (22%) and placebo (0%). A significantly ( P < 0.05) higher percentage of subjects with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10). Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg group. The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with allopurinol. Conclusion: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.

Overview

Integrity signals

Registry

Crossref · 10.1002/art.24209

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 43 references

Research works printed but not linked: 2

  1. 2001, Allopurinol tablets, USP [package insert]
  2. Grabowski BA, 2005, Absorption, metabolism and excretion of [14C]febuxostat, a novel non‐purine selective inhibitor of xanthine oxidase, in healthy male subjects, Drug Metab Rev, 37, 111

Cited by

Sorted by citations

Items 301–400 of 641

Related

See all

Metadata

Authors
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N.
Affiliations
  • Philadelphia VA Medical Center (US)
  • University of Chicago (US)
  • Dartmouth College (US)
  • Takeda (United States) (US)
ORCID
Becker, Michael A.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2008-10-30
Volume
59
Issue
11
Pages
1540-1548
ISSN
  • 0893-7524 (ISSN-L)
  • 1529-0123
DOI
10.1002/art.24209
OpenAlex
W2000166571
Cited by
638
References
43
Citations by year
2026: 20 · 2025: 33 · 2024: 26 · 2023: 23 · 2022: 31 · 2021: 26 · 2020: 44 · 2019: 45 · 2018: 48 · 2017: 43 · 2016: 48 · 2015: 38 · 2014: 44 · 2013: 36 · 2012: 33
FWCI
26.55
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Arthritis Care & Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Takeda Pharmaceuticals North America
Topics
  • Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
  • Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
febuxostat, allopurinol, hyperuricemia, gout, urate-lowering therapy, renal dysfunction, gout flares, adverse events, drug safety, dose comparison, xanthine oxidase inhibitors, gout prevention, gouty nephropathy
MeSH terms
Febuxostat, Adult, Aged, Allopurinol, Creatinine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gout, Gout Suppressants, Humans, Male, Middle Aged, Thiazoles, Uric Acid, Treatment Outcome, Hyperuricemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review